Literature DB >> 10568758

Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis.

F Negro1, K Samii, L Rubbia-Brandt, R Quadri, P J Male, J P Zarski, M Baud, E Giostra, P Beris, A Hadengue.   

Abstract

Chronic hepatitis C is often associated with liver iron overload, which may affect the long-term prognosis and the response to antiviral treatment. The occurrence of hemochromatosis (HFE) mutations were studied to determine whether may contribute to the liver iron overload of chronic hepatitis C patients. The prevalence of two HFE mutations (C282Y and H63D) in 120 chronic hepatitis C patients was determined and the findings were correlated with clinical, histological and virological features. Hepatic iron was determined semiquantitatively by a histochemical hepatic iron index, defined as the ratio of a histochemical staining score to the patient's age, after correction for heterogeneous lobular iron distribution. Serum hepatitis C virus (HCV) RNA was measured by bDNA assay and typed by restriction fragment length polymorphism. Liver HCV RNA was measured by a semi-quantitative strand-specific reverse transcription-polymerase chain reaction (RT-PCR). Excess liver iron was stained in the liver of 36 patients (30%). Siderotic patients had the same geographic origin, serum and liver HCV RNA levels and H63D and C282Y mutations frequency as non-siderotic patients. However, siderotic patients were older (P = 0.015), more frequently males (P = 0.02), less frequently infected with HCV genotype 3 (P = 0.037) and had a higher liver fibrosis score (P = 0.008). The liver iron content did not correlate with the serum or liver HCV RNA titers. Ten of the 36 patients with liver siderosis had neither a history of excess alcohol intake, multiple transfusions, or HFE mutations. In conclusion, the pathogenesis of the liver iron overload in chronic hepatitis C patients cannot be fully explained by the occurrence of HFE mutations. The exact mechanism of iron accumulation in these patients therefore remains unexplained. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10568758

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

Review 1.  Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy.

Authors:  Giada Sebastiani; Alfredo Alberti
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

2.  Serum iron levels and hepatic iron overload in nonalcoholic steatohepatitis and chronic viral hepatitis.

Authors:  Suleyman Uraz; Cem Aygun; Abdullah Sonsuz; Gulsen Ozbay
Journal:  Dig Dis Sci       Date:  2005-05       Impact factor: 3.199

Review 3.  The role of iron in the pathophysiology and treatment of chronic hepatitis C.

Authors:  Leslie Price; Kris V Kowdley
Journal:  Can J Gastroenterol       Date:  2009-12       Impact factor: 3.522

4.  Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype.

Authors:  Sven G Gehrke; Wolfgang Stremmel; Inge Mathes; Hans-Dieter Riedel; Karin Bents; Birgit Kallinowski
Journal:  J Mol Med (Berl)       Date:  2003-10-14       Impact factor: 4.599

5.  The effect of iron depletion on chronic hepatitis C virus infection.

Authors:  Massimo Franchini; Giovanni Targher; Franco Capra; Martina Montagnana; Giuseppe Lippi
Journal:  Hepatol Int       Date:  2008-05-08       Impact factor: 6.047

Review 6.  HFE gene in primary and secondary hepatic iron overload.

Authors:  Giada Sebastiani; Ann-P Walker
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.